Opdivo and Yervoy combination improves overall survival by 26% in advanced melanoma compared to Yervoy alone, with a two-year OS rate of 64% versus 54%. Toxicity management and patient selection are ...

Burkitt's lymphoma is a rare and aggressive blood cancer characterized by a translocation of the MYC gene. It occurs most ...

Dr. Edgardo Santos explains that combining Tagrisso with chemotherapy or Leclaza plus Rybrevant may improve survival versus monotherapy alone. Treating patients with combination therapy approaches may ...

Achieving long-term remission is what drives multiple myeloma researchers as they strive to deliver novel therapies and combinations for people living with this disease. The progress has been ...

– Findings Support Continued Evaluation of Novel Strategies including Broadly Neutralizing HIV Antibodies, Vaccine Candidates, and TLR Agonists – A fourth pre-clinical study in a macaque model ...